Discover 1,670 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,670
Active & Responsive
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
for
HER2-positive Early-stage Breast Cancer
Location: Hamilton NJ, New Brunswick NJ, Somerville NJ,
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18 - 70+
Code: NCT07402473
Phase 2, Recruiting
Active & Responsive
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
for
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms,
Location: Hamilton NJ, New Brunswick NJ, Somerville NJ,
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18+
Code: NCT07158164
Recruiting
Active & Responsive
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
for
Obesity, Overweight, Diabetes Mellitus, Type 2
Location: Trenton NJ, Annapolis MD, Burke VA, East Greenwich RI,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07684144
Phase 3, Recruiting
Active & Responsive
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
for
Colorectal Cancer
Location: Monroe NJ, Somerset NJ, East Brunswick NJ,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT07750158
Phase 3, Recruiting
Active & Responsive
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
for
Heart Failure With Preserved Ejection Fraction,
Location: Somerset NJ, Horsham PA, Staten Island NY, Newark NJ,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07037459
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
EASi-PROTKT⢠- A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Location: East Brunswick NJ, Myrtle Beach SC, Grand Rapids MI,
Sponsor: Flare Therapeutics Inc.
Sex: Male
Age: 18+
Code: NCT07719361
Phase 1, Recruiting
Active & Responsive
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
for
Colorectal Cancer
Location: East Brunswick NJ, New York NY, Fairfax VA,
Sponsor: Verastem, Inc.
Sex: All
Age: 18+
Code: NCT07659795
Phase 2, Recruiting
Active & Responsive
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
for
Primary Immune Thrombocytopenia (ITP),
Location: East Brunswick NJ, Summit NJ, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07421167
Phase 2, Recruiting
Active & Responsive
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
for
Prostate Cancer Castration-resistant Prostate Cancer,
Location: East Brunswick NJ, Fairfax VA, Grand Rapids MI,
Sponsor: MBrace Therapeutics
Sex: All
Age: 18+
Code: NCT07145255
Phase 1, Phase 2, Recruiting
Active & Responsive
DBC-664 in Adult Patients With Solid Tumors
for
Malignant Germ Cell Tumor, Lung Adenocarcinoma,
Location: East Brunswick NJ, Lake Success NY, Grand Rapids MI,
Sponsor: Duboce Biopharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07705035
Phase 1, Recruiting
Active & Responsive
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
for
Extensive Stage-small Cell Lung Cancer
Location: East Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT06362252
Phase 1, Phase 2, Recruiting
Active & Responsive
Extensions of Resurgence as Choice
for
Problem Behavior, Aggression, Self-Injury
Location: Somerset NJ
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 3 - 17
Code: NCT05537610
Recruiting
Active & Responsive
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies